QSC Tirzepatide (LY3298176) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for type 2 diabetes research. This compound demonstrates superior efficacy in glucose control and weight management compared to selective GLP-1 receptor agonists.
The qsc tirzepatide molecule exhibits greater affinity for GIP receptors while maintaining significant activity at GLP-1 receptors. This unique dual mechanism has shown promising results in preclinical studies for improving glycemic control. Research indicates qsc tirzepatide mimics the actions of natural GIP at the GIP receptor while providing sustained GLP-1 activity.
Our qsc tirzepatide is supplied as a high purity white powder with rigorous quality control. Each batch undergoes comprehensive analytical testing including HPLC purity verification to ensure consistent quality for research applications.
For laboratory research use only. Not for human consumption. Proper storage conditions are essential to maintain stability - store at -20°C for long-term preservation.